Who is sponsoring NCT00804141?

NCT00804141 is sponsored by Bausch Health Americas, Inc..

What condition does NCT00804141 study?

NCT00804141 studies Constipation.

What drugs are being tested in NCT00804141?

Interventions: N-methylnaltrexone bromide (MOA-728).

What is the status of NCT00804141?

NCT00804141 is currently COMPLETED.

Last reviewed 2019-10-18 · How we verify

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141 PHASE3 COMPLETED Results posted

This study is designed to evaluate the long-term safety and tolerability of the subcutaneous (SC) injection form of N-methylnaltrexone bromide (MOA-728) for the treatment of opioid-induced constipation in participants with nonmalignant pain. The study consists of a 2-week screening period, a 48-week open-label treatment period and a 2 week follow-up period. Participants will need to agree to self-administer SC injections, complete daily diaries, and check-in via a daily telephone call during the study.

Details

Lead sponsor	Bausch Health Americas, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	1040
Start date	Wed Dec 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Constipation

Interventions

N-methylnaltrexone bromide (MOA-728)

Countries

Colombia, South Korea, Canada, Australia, United States, Spain